Le Lézard
Classified in: Health
Subjects: LBR, CPG

Private Health Care Will Hurt Ontarians: Ontario Nurses' Association Urgently Calls on Government to Consult Front-Line Providers


TORONTO, Feb. 4, 2019 /CNW/ - The privatization of parts of Ontario's health-care system has the Ontario Nurses' Association (ONA) deeply concerned about the impact on health-care professionals and patient care.

Ontario Nurses' Association (CNW Group/Ontario Nurses' Association)

ONA is calling for the province to maintain the publicly delivered, publicly funded system and consult now with front-line health-care providers before implementing changes to the health-care system.

"ONA represents more than 65,000 registered nurses and health-care professionals delivering care across this province," notes ONA President Vicki McKenna, RN. "We are there at our patients' side throughout the health-care system, delivering high-quality care to those in hospitals, long-term care, in the community, in clinics, public health units and even in industry. It is absolutely vital that before any restructuring of health care occurs, the government consult with us."

McKenna adds that nurses know the challenges facing the province and has a wealth of knowledge and advice to offer. Nurses also know that privatizing health-care delivery will not benefit anyone but for-profit corporations.

"Experience in home-care delivery has shown us that private, for-profit delivery is detrimental to not only our clients but to taxpayers," said McKenna. "Why would any of us, as taxpayers, want our public dollars to go to for-profit companies?"

McKenna said that ONA is monitoring potential changes to the health-care system closely and is available to share front-line nurses' knowledge with government to improve the system.

ONA is the union representing more than 65,000 registered nurses and health-care professionals, as well as 18,000 nursing student affiliates, providing care in hospitals, long-term care facilities, public health, the community, clinics and industry.

 Visit us at: www.ona.org; Facebook.com/OntarioNurses; www.Twitter.com/OntarioNurses

SOURCE Ontario Nurses' Association


These press releases may also interest you

at 07:45
Sensi.AI Appoints Renowned Home Care Advocate, Bob Roth, to its Advisory Board Combining Data-Driven Insights with Decades of Home Care Expertise to Revolutionize Aging in Place
Sensi.AI, a leader in AI-native, data, and analytics in senior care, today announced the appointment of in-home care leader Bob Roth to its Advisory Board. This partnership is an exciting validation of Sensi.AI's promise to enhance proactive,...

at 07:05
Executive War College to Address, Clinical Laboratories' and Genetic Testing Firms' Perfect Storm, involving FDA's Proposed LDT Rule, Payers Requiring Z-Codes on Genetic Test Claims, and Revisions to CLIA Regulations
Three major challenges poised to confront the nation's clinical laboratories, genetic test companies, and anatomic pathology laboratories will be major topics when a top-flight roster of lab experts, innovators, and lab leaders gather in New Orleans...

at 07:05
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday,...

at 07:04
Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy
Merck , known as MSD outside the United States and Canada, announced that Health Canada has granted approval of  KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the...

at 07:00
GLOBE LIFE INC. ANNOUNCES FIRST QUARTER 2024 EARNINGS RELEASE AND CONFERENCE CALL
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024.  At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...

at 07:00
GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a...

More news about Health...


News published on and distributed by: